Everything You Need to Know About Oral hypoglycemics (metformin, sulfonylureas, SGLT2i, GLP-1 agonists, DPP-4i) for Step 1

Diabetes questions on Step 1 love to pivot from “what type of diabetes is this?” to “which drug fixes the physiology and what side effect gives it away?” Oral (and “non-insulin”) hypoglycemics are perfect test bait because they’re mechanism-heavy, pathophysiology-driven, and packed with classic adverse effects. This post is a deep, Step 1–focused tour of metformin, sulfonylureas, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors—with high-yield associations and First Aid-style cross-references.

---

Big-Picture: What Are “Oral Hypoglycemics” Trying to Fix?

The core pathophysiology of Type 2 DM (Step 1 framing)

Type 2 diabetes is primarily:

• Insulin resistance in peripheral tissues (muscle/adipose)
• Relative insulin deficiency over time from progressive $\beta$-cell dysfunction

This leads to:

• Hyperglycemia (increased hepatic gluconeogenesis + impaired glucose uptake)
• Hyperinsulinemia early, then insulin levels drop as $\beta$ cells fail

Therapy logic (what Step 1 wants you to connect):

• Lower hepatic glucose output → metformin
• Increase endogenous insulin release → sulfonylureas
• Dump glucose through urine → SGLT2 inhibitors
• Boost glucose-dependent insulin release + satiety, slow gastric emptying → GLP-1 agonists
• Prevent incretin breakdown (milder incretin effect) → DPP-4 inhibitors

💡

First Aid cross-reference: Endocrine → Diabetes mellitus → “Oral hypoglycemics” tables (commonly found in the diabetes pharm pages/section).

---

Clinical Presentation & Diagnosis (The Setup Before the Drug Question)

Classic presentation

• Polyuria, polydipsia
• Blurry vision, fatigue
• Recurrent infections (candida, skin)
• Type 2 often with obesity, acanthosis nigricans, HTN, dyslipidemia

Diagnosis thresholds (know these cold)

Any of the following (confirmed on repeat testing unless classic symptoms + random glucose):

• Fasting plasma glucose $\ge 126$ mg/dL
• HbA1c $\ge 6.5\%$
• 2-hr OGTT $\ge 200$ mg/dL (75 g glucose)
• Random glucose $\ge 200$ mg/dL + symptoms

💡

Step 1 pearl: HbA1c reflects ~3 months of glycemic control (RBC lifespan). Conditions altering RBC turnover can skew it.

---

High-Yield Drug Map (Mechanism → Effect → Side Effects)

Quick comparison table (Step 1 speed run)

---

Metformin (Biguanide): The “First-Line” Physiology Fix

Definition & mechanism (high yield)

Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity (especially in muscle/adipose).
Also tends to modestly:

• ↓ intestinal glucose absorption
• Improve lipid profile (mild)

Key Step 1 point: Metformin does not increase insulin secretion → minimal hypoglycemia when used alone.

💡

First Aid cross-reference: Diabetes pharm table: “Biguanides—Metformin—↓ gluconeogenesis.”

Clinical use (board logic)

• First-line in Type 2 DM (unless contraindicated)
• Particularly good when insulin resistance/obesity is prominent
• Often combined with other agents

Adverse effects & contraindications (classic question stem)

• GI upset (nausea, diarrhea)
• Lactic acidosis (rare but testable)
  • Risk increased with renal failure (decreased clearance), severe hypoxia, liver failure, alcoholism
• Contraindicated in significant renal dysfunction (Step 1 simplified: “renal failure = no metformin”)

Board-style vignette clue:
Patient with T2DM + CKD develops malaise, myalgias, respiratory distress, ↑ anion gap metabolic acidosis → think metformin-associated lactic acidosis.

---

Sulfonylureas: “Close the KATP Channel” (and cause hypoglycemia)

Mechanism (the most testable detail)

Sulfonylureas close ATP-sensitive $K^+$ channels on pancreatic $\beta$ cells → membrane depolarization → Ca$^{2+}$ influx → insulin release.

That mechanism is the same channel targeted by:

• Sulfonylureas (close it)
• Meglitinides (not in your requested list, but same concept)

💡

First Aid cross-reference: “Sulfonylureas—close $K_{ATP}$ channels—↑ insulin release.”

Clinical implications

• Require functioning $\beta$ cells → won’t work in Type 1 DM
• Higher hypoglycemia risk than metformin or incretin-based therapies

Adverse effects (Step 1 favorites)

• Hypoglycemia (biggest)
• Weight gain
• Disulfiram-like reaction (classically 1st generation, especially chlorpropamide)
• SIADH (chlorpropamide association)

Board-style vignette clue:
Elderly patient on glyburide with diaphoresis, confusion, tremor → hypoglycemia from sulfonylurea.

---

SGLT2 Inhibitors: “Pee Out the Glucose” (and sometimes ketones)

Mechanism

SGLT2 inhibitors block SGLT2 in the proximal convoluted tubule, reducing glucose reabsorption → glucosuria and osmotic diuresis.

💡

First Aid cross-reference: “SGLT2 inhibitors—canagliflozin, dapagliflozin—↓ glucose reabsorption in PCT.”

Clinical effects (what stems hint at)

• Modest weight loss
• Mild BP reduction (due to diuresis)
• Low hypoglycemia risk when used alone (not pushing insulin directly)

High-yield adverse effects

• Genital mycotic infections (candida vulvovaginitis, balanitis)
• UTIs (often mentioned)
• Volume depletion → dizziness, hypotension, ↑ BUN/Cr
• Euglycemic DKA (super high yield concept)
  • Ketosis + acidosis with near-normal glucose
  • Triggered by low insulin states (illness, decreased intake, peri-op), more common with SGLT2 inhibitors

Board-style vignette clue:
T2DM patient on an SGLT2 inhibitor with abdominal pain, nausea, Kussmaul respirations, high anion gap metabolic acidosis, glucose ~150–250 → think euglycemic DKA.

---

GLP-1 Receptor Agonists: Incretins That Help You Lose Weight

Incretin physiology (pathophys tie-in)

GLP-1 is an incretin released from the gut after meals that:

• ↑ glucose-dependent insulin secretion
• ↓ glucagon
• ↓ gastric emptying
• ↑ satiety

GLP-1 agonists mimic this, but are resistant to breakdown (relative to native incretins).

💡

First Aid cross-reference: “GLP-1 analogs—exenatide, liraglutide—↑ insulin, ↓ glucagon, ↓ gastric emptying.”

Step 1 clinical patterns

• Great for patients where weight loss is beneficial
• Low hypoglycemia risk alone (glucose-dependent insulin release)

High-yield adverse effects

• GI effects (nausea, vomiting)
• Pancreatitis (classic association)
• “Thyroid C-cell tumor risk” warning (board-style association; stems may mention MEN2 history/thyroid cancer concern)

Board-style vignette clue:
Patient started on exenatide develops severe epigastric pain radiating to the back with elevated lipase → suspect pancreatitis.

---

DPP-4 Inhibitors: “Protect Endogenous GLP-1” (Milder, Weight-Neutral)

Mechanism

DPP-4 breaks down incretins (GLP-1, GIP). DPP-4 inhibitors block this enzyme → ↑ endogenous incretin levels → ↑ glucose-dependent insulin release and ↓ glucagon.

💡

First Aid cross-reference: “DPP-4 inhibitors—sitagliptin, saxagliptin—↑ endogenous incretins.”

Step 1 clinical patterns

• Generally weight-neutral
• Low hypoglycemia risk alone

High-yield adverse effects

• Pancreatitis (also shows up here)
• URTI-like symptoms (nasopharyngitis) are commonly tested as a “soft” association
• Severe joint pain is a known association sometimes used as a clue

Board-style vignette clue:
Patient on sitagliptin with pancreatitis symptoms (epigastric pain, ↑ lipase) → suspect DPP-4 inhibitor adverse effect.

---

Putting It Together: How Step 1 Asks These

Common question formats

1. Mechanism ID from a stem

   • “Drug increases endogenous insulin by closing ATP-sensitive potassium channels” → sulfonylurea
   • “Drug increases urinary glucose excretion” → SGLT2 inhibitor

2. Adverse effect ID

   • Metformin + CKD + acidosis → lactic acidosis
   • SGLT2 inhibitor + genital itching/discharge → mycotic infection
   • GLP-1 agonist/DPP-4 inhibitor + pancreatitis symptoms → pancreatitis

3. Type 1 vs Type 2 logic

   • Sulfonylureas won’t work in Type 1 (no functioning $\beta$ cells)
   • Metformin addresses insulin resistance (Type 2 core problem)

---

High-Yield “Associations” Checklist (Memorize This)

• Metformin

  • MOA: ↓ gluconeogenesis, ↑ insulin sensitivity
  • AE: lactic acidosis, GI upset
  • Avoid: renal failure

• Sulfonylureas

  • MOA: close $K_{ATP}$ in $\beta$ cells → ↑ insulin
  • AE: hypoglycemia, weight gain
  • 1st gen: disulfiram-like, SIADH (chlorpropamide)

• SGLT2 inhibitors

  • MOA: block PCT glucose reabsorption → glucosuria
  • AE: genital mycotic infections, dehydration, euglycemic DKA

• GLP-1 agonists

  • MOA: ↑ glucose-dependent insulin, ↓ glucagon, ↓ gastric emptying
  • Benefits: weight loss
  • AE: pancreatitis, GI effects

• DPP-4 inhibitors

  • MOA: inhibit incretin breakdown → ↑ endogenous GLP-1
  • Weight neutral
  • AE: pancreatitis, URTI symptoms/joint pain associations

---

Mini Self-Test (Rapid Fire)

1. A T2DM patient starts a drug that increases insulin secretion by depolarizing pancreatic $\beta$ cells. What ion channel is directly affected?

• ATP-sensitive $K^+$ channel (closed by sulfonylureas)

2. A patient on a new diabetes drug develops ketoacidosis with glucose 180 mg/dL. What class is most likely responsible?

• SGLT2 inhibitor

3. Which drug class is most associated with lactic acidosis risk in renal failure?

• Metformin